US Patent

US8337824 — Linear polyol stabilized polyfluoroacrylate compositions

Method of Use · Assigned to Relypsa Inc · Expires 2030-05-29 · 4y remaining

Vulnerability score 76/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions of a linear polyol and a salt of a crosslinked cation exchange polymer that bind potassium in the gastrointestinal tract.

USPTO Abstract

The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1766 — patiromer-sorbitex-calcium
U-1766 — patiromer-sorbitex-calcium
U-1766 — patiromer-sorbitex-calcium
U-1766 — patiromer-sorbitex-calcium

Patent Metadata

Patent number
US8337824
Jurisdiction
US
Classification
Method of Use
Expires
2030-05-29
Drug substance claim
Yes
Drug product claim
No
Assignee
Relypsa Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.